James Hok-Fung Chan
Tumour hypoxia represents a major obstacle for cancer therapies. In order to improve the effectiveness of cancer treatments, a better understanding of cellular responses in tumour hypoxia is urgently needed.
My current research studies the roles of the tumour suppressor ASPP2 in tumour hypoxia. Using a multi-omics approach, including ChIP- and RNA-sequencing, together with bioinformatics from patient samples, we seek to understand how ASPP2 regulates the major signalling pathways in hypoxia and how the dysfunction of ASPP2 may impact the adaptation of tumour cells to hypoxia.